SUN-142 High Prevalence of NAFLD and Advanced Fibrosis in Patients with Obesity and Diabetes

por Barb, Diana, Repetto, Enrico, Stokes, Michael, Shankar, Sudha, Cusi, Kenneth
Publicado 2019

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease

por Barb, Diana, Repetto, Enrico M., Stokes, Michael E., Shankar, Sudha S., Cusi, Kenneth
Publicado 2021

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

por Gastaldelli, Amalia, Repetto, Enrico, Guja, Cristian, Hardy, Elise, Han, Jenny, Jabbour, Serge A., Ferrannini, Ele
Publicado 2019

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)

por Mathieu, Chantal, Dandona, Paresh, Birkenfeld, Andreas L, Hansen, Troels Krarup, Iqbal, Nayyar, Xu, John, Repetto, Enrico, Scheerer, Markus Florian, Thoren, Fredrik, Phillip, Moshe
Publicado 2020